Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C in obese adults without diabetes
NL-OMON41005Phase 2Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of efpeglenatide in obesity, Overweight, sponsored by Hanmi Pharmaceutical. Started Jun 2014; status: active, not recruiting.
02
Drugs
efpeglenatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON41005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41005.